Baxter International Inc.

Baxter Healthcare Inc.

Robert J Przybelski

Kenneth E Burhop

John D Blue

Jan W Garber

Gary R Marchand

Janet C Gonder

Kathleen N Stern

A method of treating a mammal suffering from hypotension by administering intermolecularly- or intramolecularly-crosslinked stroma-free hemoglobin to the mammal.

Use of hemoglobin in the treatment of hypotension

Low doses of stroma-free diaspirin cross-linked hemoglobin are administered to patients undergoing hemodialysis, to achieve hemostabilization and avoid hypotensive episodes in susceptible patients. Hemoglobin therapy when implemented prophylactically in hemodialysis also partially obviates the need for further interventions to control circulatory system instability.

Hemoglobin therapy in hemodialysis

Therapeutic treatment of septic shock comprises administering to an animal stroma-free hemoglobin, typically at a dose ranging from the least amount effective to increase perfusion, up to a dosage of about 2500 milligrams kilograms per of body weight.

Use of hemoglobin to treat septic shock

A method for increasing perfusion in a mammal suffering from cardiogenic shock by administering a perfusion-increasing effective amount of intermolecularly- or intramolecularly-crosslinked stroma-free hemoglobin to the mammal.

Use of hemoglobin in the treatment of cardiogenic shock

A method for increasing perfusion in a mammal suffering from stroke by admninistering a perfusion-increasing effective amount of intermolecularly- or intramolecularly-crosslinked stroma-free hemoglobin to the mammal.

Use of hemoglobin in the treatment of stroke

A method for treating systemic inflammatory response syndrome in a mammal by administering to the mammal a hemoglobin preparation after the mammal is diagnosed as suffering from systemic inflammatory response syndrome, wherein the systemic inflammatory response syndrome is a condition other than sepsis.

Use of hemoglobin to treat systemic inflammatory response syndrome

A method of treating a mammal suffering from hemorrhagic shock or reducing hypotension secondary to hemorrhagic shock in a mammal suffering from hemorrhagic shock by administering intermolecularly- or intramolecularly-crosslinked stroma-free hemoglobin to the mammal.

Use of hemoglobin in the treatment of hemorrhagic shock

This invention provides a method to therapeutically increase perfusion in a mammal comprising administering stroma-free hemoglobin at a dose ranging from the least amount effective to increase perfusion, up to a dose of about 2500 mg per kilogram of body weight.

Growing community of inventors

Antioch, IL, United States of America

Robert J Przybelski